No Data
No Data
Veracyte Price Target Maintained With a $45.00/Share by Stephens & Co.
Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests
Veracyte Announces New Data Showing That Its Whole-Genome Sequencing (Wgs)-Based Platform For Minimal Residual Disease Testing Detected Cancer In Patients Treated for Muscle-Invasive Bladder Cancer With More Accuracy Than Ddpcr-Based Blood Testing And...
Express News | Veracyte Inc - to Launch First Mrd Test for Mibc in H1 2026
Express News | New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based Mrd Testing Platform for Muscle-Invasive Bladder Cancer
Craig-Hallum Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $45
Unlock the Full List